Introduction
============

Esophageal carcinoma is the eighth most common cancer and the sixth leading cause of cancer mortality worldwide.[@b1-ott-11-1305] It consists of various histological types with different incidence patterns. Among them, two histopathological types -- esophageal adenocarcinoma and esophageal squamous cell carcinoma (ESCC) -- are the most common. Even so, they still have different cells of origin, risk factors, and causality. In the United States, 15,590 deaths and 16,980 new esophageal cancer cases were estimated to occur in 2015.[@b2-ott-11-1305] In some high-risk regions, especially in developing countries, including People's Republic of China and other East Asian countries, ESCC is responsible for 90% of all cases with an increasing incidence rate.[@b3-ott-11-1305] Initially, barium esophagography is widely used for assessment in patients who present with progressive dysphagia symptoms of esophageal carcinoma. Currently, more examination techniques such as computed tomography (CT), magnetic resonance imaging, positron emission tomography-CT, endoscopic ultrasonography, and minimally invasive staging biopsy have been used for its diagnosis. Also, some new methods such as chemotherapy, radiotherapy, and minimally invasive esophagectomy have been used to treat esophageal cancer;[@b1-ott-11-1305] nevertheless, the prognosis of patients remains poor and the 5-year overall survival (OS) is only 26.2%--49.4% after surgery.[@b4-ott-11-1305]

So it is urgent to identify effective and independent markers for early diagnosis and clinical prognostic prediction. During the past years, researchers worked on in-depth analysis of biological factors associated with malignant behavior and the signaling pathway outcome for certain molecules. Significantly, some new therapies to target tissue polypeptide antigen have been applied. An increasing number of related schemes are becoming available. Nuclear factor-κB (NF-κB) has already been identified as a transcription factor, which combines with a DAN element in B cell kappa immunoglobulin light-chain enhancer.[@b5-ott-11-1305] It is characterized by a conserved 300 amino acid Rel homology domain located in the N terminus of the protein, and is used to bind DNA. NF-κB could dimerize DNA and cause the cells to become cancerous. Meanwhile, it also interacts with specific inhibitory factors known as IκB proteins.[@b6-ott-11-1305] NF-κB mediates apoptotic signaling pathways in different types of human cancers.[@b7-ott-11-1305],[@b8-ott-11-1305] Some studies have shown that antiapoptotic function of activated NF-κB was an obstacle to cancer therapy.[@b9-ott-11-1305],[@b10-ott-11-1305] Thus, we consider whether suppressing NF-κB signaling will show an important step in the process of optimal antiesophageal cancer therapies. Normally, NF-κB complexes are sequestered in unstimulated cytoplasm as homo-heterodimers bound to IκB proteins. In stimulated cells, with tumor necrosis factor, interleukin-1, or protein kinase cascades, IκB can be phosphorylated, ubiquitinated, and subsequently degraded.[@b11-ott-11-1305] This will result in NF-κB translocation to the nucleus and increased expression of NF-κB-regulated genes. Of course, there are a large number of active complexes to phosphorylate IκB. For example, inhibitor of NF-κB kinase epsilon (IKBKE, IKKε) is a serine/threonine kinase that belongs to the IKK family, which includes IKKα, IKKβ, IKKε, and TBK1.[@b12-ott-11-1305],[@b13-ott-11-1305] Comparing the amino acid sequences of IKKα, IKKβ, and IKKε showed significant sequence similarities. They have similar molecular weights of about 85 kDa, and their functional domains are approximately organized. IKKε together with IKKα and IKKβ activate the NF-κB pathway by phosphorylation and degradation of IκB.[@b14-ott-11-1305],[@b15-ott-11-1305] Among these IKK proteins, IKBKE protein exhibits 31% and 33% identities at the amino acid level.[@b16-ott-11-1305] Also, only IKBKE has been proven to be overexpressed in cancers, including upregulation in ovarian cancer, prostate cancer, breast cancer, and nonsmall-cell lung carcinoma (NSCLC).[@b17-ott-11-1305],[@b18-ott-11-1305] However, two studies have focused on the role of IKKε in immunity and inflammation.[@b19-ott-11-1305],[@b20-ott-11-1305] The molecular basis of IKKε overex-pression in tumors is still unknown.

Despite these previous research studies, little is known about IKBKE expression and its exact role in esophageal carcinoma. Therefore, in this report, through clinicopatho-logical analysis of esophagus lesions sampled from esophageal cancer patients, we investigate the relationship between IKBKE expression and tumor malignant level and prognosis. These findings suggest that IKKε could be a therapeutic target and prognostic marker for this malignancy.

Materials and methods
=====================

Patients and specimens
----------------------

Between January 1st and December 31st 2013, 118 patients with ESCC who received radical surgery in the Department of Thoracic Surgery at Qilu Hospital of Shandong University, Jinan, People's Republic of China were admitted into our retrospective study. The patients had the same surgical procedure -- transthoracic esophageal resection. All patients had undergone left or right thoracotomy for curative resection by subtotal or total thoracic esophagectomy, as well as at least a two-field lymphadenectomy. No patient underwent transhiatal esophagectomy. The final day guaranteed a minimum follow-up of 36 months for all included patients. Patients did not receive radiotherapy and chemotherapy before surgery. Patients were already excluded because of stage 0 disease, distant metastasis, resection not for curative intent, lack of tumor tissue, and loss to follow up. Both pathological reports and hematoxylin and eosin (H&E)-stained tissue from the primary tumor were collected from the Department of Pathology at Qilu Hospital of Shandong University. The tumor stage was divided according to the American Joint Committee on Cancer 7th edition staging manual. All of the data, including age, gender, drinking and smoking habit, histologic grade, invasion depth, lymph node metastasis, distant metastasis (pTNM stage), and number of dissected lymph nodes, was abstracted from the clinical or pathologic records. The study was approved by the Ethics Committee of Qilu Hospital of Shandong University.

Follow-up
---------

All patients were regularly followed up by telephone every 3 months during the first 2 years after surgery. Subsequently, their information was acquired every 6 months to the end of the study (December 2016) or death. Additional interim visits were scheduled if complaints such as unexplained weight loss (more than 10% of the original body weight), pain, or renewed dysphagia arose before the next scheduled follow-up. Follow-up items included a clinical history, a physical examination, laboratory blood or urine tests, barium meal fluoroscopy, and CT. The endpoints of study were 3-year disease-free survival (DFS) and 3-year OS. DFS was measured as the time interval following surgery that patients lived free of tumor or the earliest advancement that occurred including locoregional recurrence, distant dissemination, or death from any cause. OS was the time interval from the surgery date to the last day of follow-up or the date of death.

Immunohistochemical analysis
----------------------------

IKBKE protein expression was examined in the 118 ESCC surgical specimens using immunohistochemistry (IHC). Briefly, 4-μm-thick formalin-fixed paraffin-embedded sections were baked at 70°C for 1 h. The sections were deparaffinized with xylenes, and rehydrated through a graded ethanol series. Then, we placed specimens in EDTA antigen retrieval buffer and microwaved them. Endogenous peroxidase activity was blocked using a solution of 3% hydrogen peroxide in methanol. Nonspecific binding sites were blocked through 20-min incubation in 1% bovine serum albumin at room temperature. The sections were incubated with anti-IKBKE rabbit polyclonal antibody (1:100, Anti-IKKi/IKKe antibody \[EPR4904\]; Abcam, Shanghai, People's Republic of China) by the manufacturer's protocol with some modification at 4°C overnight.

The anti-IKBKE antibody was performed for the specimen for at 37°C for 1 hour. Then the PBS was utilized to wash the section three times for 5 minutes at a time. Normal goat serum was applied as a negative control replacing the primary antibody. After incubation with biotinylated anti-rabbit secondary antibody for 30 min, the specimen was incubated with streptavidin alkaline peroxidase complex (Biotin-Streptavidin HRP Detection Systems SP9000; ZSGB-Bio, Beijing, People's Republic of China). Then, the sections were color developed in AEC reagent and counterstained using 10% Mayer's hematoxylin, dehydrated. Finally, the sections were mounted with an aqueous mounting medium provided with the kit.

Evaluation of immunostaining
----------------------------

The degree of immunostaining was counted independently by two observers (Wenjing Yang and Yan Qu). IKBKE expression was considered positive when yellow particles were observed in cytoplasm. The two observers recorded the average number of immunopositive cytoplasms. The recorded cytoplasms were from 400 tumor cells of about 5--10 scientifically randomized fields throughout the sections. The tumor sections were selected by observing at low power magnification (×100), with the highest number of positive cell infiltration in intratumoral areas. It is worth noting that intratumoral tissue has the highest density of tumor cell infiltration. Whenever the observers encountered heterogeneous staining, counting was carried out in the areas of highest density of tumor cells and identified at medium magnification (×200), because those tumor areas are likely to be of biologic significance. No lymphoid cells were covered in the counts although they expressed IKBKE. The Axio Vision Rel. 4.6 (Carl Zeiss, Meditec AG, Jena, Germany) computerized image analysis system was used to analyze the difference in IHC stain intensities in tumors.

Statistical analysis
--------------------

All data analyses were conducted using the SPSS 16.0 (SPSS Inc., Chicago, IL, USA) statistical software package. Statistical analysis was shown by paired-sample *t*-test to contrast quantitative variables between groups. The associations between IKBKE expression and clinicopathological features, such as tumor T categorization, clinical stage, and lymph node metastasis status, were verified using Fisher exact tests or Pearson's *χ*^2^ tests. Spearman's rank correlation coefficient was used to determine the associations between numerical variables. Survival curves were plotted by the Kaplan--Meier method and compared using the log rank test. Also, in order to identify independent prognostic factors, we used Cox's proportional hazards model through multivariate analysis. Two-sided *p*-values \<0.05 were regarded as significant.

Results
=======

Clinicopathological characteristics of patients
-----------------------------------------------

The clinicopathologic characteristics of our 118 patients are shown in [Table 1](#t1-ott-11-1305){ref-type="table"}. This study included 23 (19.5%) females and 95 (80.5%) males. The median age of all patients was 60.5 years, ranging from 42 to 78 years at the date of surgery. Tumor location was the cervical esophagus in 3 patients; 66 (55.9%) patients' tumor location was in the middle third of the thoracic esophagus while 37 (31.4%) patients' tumor occurred in the thoracic lower, and only about 12 (10.2%) patients' tumor location was located in the upper third. The median length of the primary tumor was 3.5 cm (range, 0.5--8.5 cm). Forty-three patients (36.4%) had T1/T2 tumors, but others were T3/T4. When it came to the histopathological differentiation, 32 cases were well and 51 cases were moderate. There were 47 (39.8%) patients with positive lymph nodes, and the number of lymphatic metastases exceeded 2 in 26 (22.0%) patients. The pathological stages in all patients were 18 (15.3%) stage I, 57 (48.3%) stage II, and stage III in 43 (36.4%) patients. The median follow-up was 26.5 months (range, 3--50 months). Of the 68 (57.6%) patients who suffered recurrence during the follow-up, 4 cases were surgical anastomosis recurrences, 18 cases had lymph node metastasis, 19 were local recurrences, and 27 were distant recurrences. Median DFS was 38.7 months (range, 1.5--71.5 months). Median OS was 43.5 months (range, 2.6--71.5 months). We differentiated between IKBKE expression and no expression, depending on evaluation of immunostaining. A proportion of IKBKE-expressing cells exceeding 25% was defined as high IKBKE expression and if not, then low expression. There were 73 patients with high expression, accounting for 61.9%.

IKBKE expression in ESCC and adjacent tissue
--------------------------------------------

IKBKE protein expression was mainly localized in the cytoplasm. In order to examine the difference of IKBKE expression in nontumor and tumor cells, we compared its expression in adjacent normal tissues and ESCC tumor. Representative images of IKBKE positive cell infiltration are shown in [Figure 1](#f1-ott-11-1305){ref-type="fig"}. The median proportion of IKBKE-expression cells in tumors and nontumors was 57.2% (range, 0--90.0%) and 26.1% (range, 0--53.2%), respectively ([Figure 2](#f2-ott-11-1305){ref-type="fig"}). IKBKE expression had a 1.3-fold increase in tumors. In conclusion, IKBKE was more highly expressed in ESCC tumor cells as compared to adjacent nontumor tissues (*p*=0.03), and showed a positive correlation of IKBKE expression and ESCC tumors.

Correlation of IKBKE expression with clinicopathological parameters
-------------------------------------------------------------------

The clinical characteristics of 118 ESCC patients were grouped by IKBKE low and high expression, as presented in [Table 2](#t2-ott-11-1305){ref-type="table"}. Based on the proportion of expression, 73 (61.9%) cases were assigned into the IKBKE group whereas the other 45 (38.1%) cases were assigned into the no expression group. No significant difference was discovered regarding gender, age, tumor location, tumor length, tumor thrombus, pathological tumor status, lymphatic metastasis number, and recurrence between the two groups. However, increased IKBKE expression was significantly associated with differentiation grade (*p*=0.045) and advanced pTNM stages (*p*=0.023). Furthermore, IKBKE expression was more frequently observed in poor pathologic differentiation and advanced cancer.

Correlation of IKBKE with other prognostic factors
--------------------------------------------------

We used Kaplan--Meier curves for DFS (*p*\<0.05) and OS (*p*\<0.05) based on preoperative IKBKE ([Figure 3](#f3-ott-11-1305){ref-type="fig"}). The 3-year DFS and OS for patients with IKBKE low expression were 67.1% and 71.2%, respectively, compared with 40.7% and 49.6% for patients with high expression. Patients with high preoperative IKBKE had a significant worse prognosis for DFS (*p*=0.023) and OS (*p*=0.009) than those with no IKBKE. The difference of curves between the two control groups remained statistically significant.

In order to identify variables that affect the prognosis in ESCC patients, univariate and multivariate analyses were applied to investigate the influence between IKBKE expression and other clinicopathological parameters on the prognosis for the 118 ESCC patients. In the univariate analysis of 3-year DFS and OS, the HR of IKBKE was 1.804 (95% CI 1.076--3.027; *p*=0.023) and 2.118 (95% CI 1.189--3.773; *p*=0.009), respectively ([Table 3](#t3-ott-11-1305){ref-type="table"}). In the univariate model, variables closely associated with poor DFS and OS were lymphatic metastasis number (≥2), advanced tumor stages, and advanced pTNM stages (*p*\<0.05). No prognostic importance was found for tumor location, tumor length, and differentiation grade. The multivariate analysis showed increased IKBKE expression was independently associated with decreased DFS and poor OS. The HRs for IKBKE were 1.777 (95% CI 1.034--3.054; *p*=0.037) and 2.078 (95% CI 1.138--3.796; *p*=0.017), respectively ([Table 4](#t4-ott-11-1305){ref-type="table"}). Therefore, IKBKE was an independent prognostic variable for 3-year DFS and OS.

Discussion
==========

Tumor suppressor genes and mutational proto-oncogenes permit incipient cancer cells to escape the physical normal regulation maintaining cell and tissue homeostasis. Especially, kinases play important roles in many aspects of human cancers and also are particularly attractive therapeutic targets. Therefore, several kinase inhibitors are already used in clinical treatment. The transcription factor NF-κB participates in numerous physiological processes such as immunity, inflammation, cell proliferation, and control of cell death.[@b21-ott-11-1305]--[@b23-ott-11-1305] The five members of the NF-κB family, p50 (NF-κB1), p52 (NF-κB2), p65 (RelA), cRel, and RelB, can make up different dimer combinations, but a heterodimer is the most frequently detected form between p50 and the transactivating p65 subunit.[@b24-ott-11-1305] RelA is the most abundantly and ubiquitously expressed.[@b25-ott-11-1305] Moreover, RelA is the transcriptionally active subunit of the predominant RelA--p50 dimer. Usually, p50 (NF-κB1) and p65 (RelA), the two members of the NF-κB family, are kept inactive through complex formation with inhibitory kappa B proteins (IκBs) in cytoplasm.[@b26-ott-11-1305] Optimal NF-κB activation is initiated by viral or bacterial infections through Toll-like receptors, phorbol 12-myristate 13-acetate, or interferon. This process involves the signal-induced phosphorylation and subsequent ubiquitin-mediated degradation of IκB by the classical IκB kinase (IKK)-dependent pathway.[@b25-ott-11-1305],[@b27-ott-11-1305]--[@b29-ott-11-1305] Studies have confirmed that although some dimers play a regulatory role, NF-κB proteins form dimers which canonically activate gene expression. The most prominent NF-κB dimer is present in an inactive state bound to a natural inhibitor termed IκBα. NF-κB activation is dependent on polyubiquitination that targets IκBα for degradation, releasing NF-κB dimers from the NF-κB--IκBα complex, followed by translocation to the nucleus and binding to κB enhancer elements of target genes.[@b30-ott-11-1305] In all members of the IKK kinase family, IκB kinase (IKK) epsilon (IKKε) is different from the others in identity and similarity at the amino acid level. It is a noncanonical IKK homologue, which shares 33% and 31% amino acid identity with the corresponding domains in IKKα and IKKβ, and plays an important role in activating NF-κB signaling by phosphorylating IκBα.[@b12-ott-11-1305],[@b31-ott-11-1305],[@b32-ott-11-1305] It has been well demonstrated that IKKα and IKKβ form a complex with scaffold protein IKKγ (also called NEMO) and activate NF-κB.[@b19-ott-11-1305],[@b33-ott-11-1305] We want to know whether IKKε has a similar function in ESCC. Gene deletion experiments suggested that IKKε was dispensable for the canonical NF-κB activation pathway.[@b34-ott-11-1305] However, although some late NF-κB target genes could not be upregulated in IKKε cells,[@b20-ott-11-1305] it has been presented that IKKε might regulate NF-κB at some later step. The kinase was first identified as an IKK kinase family member of the NF-κB activation by lipopolysaccharides and phorbolesters.[@b12-ott-11-1305],[@b15-ott-11-1305] IKKε mainly mediates NF-κB activation induced by the T cell receptor, phorbol 12-myristate 13-acetate, or interferon, but not by interleukin-1 and tumor necrosis factor, which activate IKBKA and IKBKB. Mattioli et al[@b32-ott-11-1305] indicated that IKKε mediated inducible phosphorylation of NF-κB p65 at serine 468 in response to T cell costimulation. This phosphorylation affected RelA/p65-dependent transactivation. Adi Mazhar et al[@b35-ott-11-1305] showed that ectopically expressed IKKε induces Ser-536 p65/RelA phosphorylation, NF-κB activation, and NF-κB-dependent gene expression. They also raised that IKKε worked in an autoregulatory loop, leading to its own expression. However, using transfection and Western blots, Koop et al[@b36-ott-11-1305] showed that phosphorylation of p65/RelA even at both sites was insufficient to activate NF-κB-driven gene expression, indicating that most likely several mechanisms were involved in IKKε-mediated NF-κB activation. Subsequently, studies[@b37-ott-11-1305] found that, independently of the classical IκB/IKK pathway, IKKε could directly phosphorylate the C-terminal domain of cRel in vivo and in vitro within two regions of the transactivation domain and regulated nuclear accumulation of cRel. IκBα degradation was not affected, but IKKε-mediated phosphorylation of cRel would result in dissociation of the IκBα--cRel complex, in a manner which was independent of IκBα Ser32 and Ser36 phosphorylation. Nevertheless, nuclear retention of phosphorylated cRel was not enough to induce strong cRel transactivation. This activation step could involve additional cRel posttranslational modification, association with chromatin modification, or coactivators.[@b37-ott-11-1305] Meanwhile, chromatin immunoprecipitation experiments were used to reveal the inducible association of IKKε to the control regions of several NF-κB target genes and nuclear NF-κB activity.[@b38-ott-11-1305] Chen et al[@b30-ott-11-1305] discovered by IHC staining and Western blot analysis that deregulation of NF-κB activity is the result of altered translation, stability, and/or phosphorylation of proteins rather than upregulation of the genes that encode proteins such as IKKε, IκBα, or NF-κB p65. However, its precise mechanism of action remains under study.

With regard to a role in cancer, IKKε has been shown to be upregulated in breast, ovarian, and endometrial cancers as well as gliomas.[@b39-ott-11-1305]--[@b41-ott-11-1305] Recently, many important functions of IKBKE were discovered. Research revealed that IKBKE can inhibit the function of cell growth inhibitor FOXO3a in NSCLC and breast cancer cells through SerS644 phosphorylation.[@b22-ott-11-1305] In breast cancer, Colas et al,[@b42-ott-11-1305] moreover, using fluorescence in situ hybridization for IKKε amplification, showed that 10 of 21 breast cancers and 13 of 17 cell lines founded IKKε protein overexpression in the absence of 1q32 copy number changes. RAS can stimulate many pathways, such as the mitogen-activated protein kinase, phosphoinositide 3 kinase, and Ral guanine nucleotide dissociation stimulator signaling pathways.[@b43-ott-11-1305] IKBKE could work as the RAS oncogene downstream effector in NSCLC cells and meanwhile mediates Ras-based active IKKεation of NF-κB and tumorigenic activity.[@b44-ott-11-1305] Beyond that, Boehm et al,[@b39-ott-11-1305] using complementary genetic approaches, identified IKBKE as a breast cancer oncogene by analyzing the downstream pathways for RAS to induce tumor transformation. In order to seek kinases that took the place of AKT in the RAS--AKT pathway to promote cellular transformation, they filtrated a myristoylated kinase expression library and identified that IKKε could replace AKT in transformation and that AKT-driven cell transformation requires NF-κB activity and IKBKE. Furthermore, researchers also found that IKKε can functionally replace the AKT oncogene to promote malignant transformation by phosphorylating Akt-Thr308 and Ser473, with AKT activation.[@b23-ott-11-1305] In this study, we did not investigate the mechanism underlying IKKε significant upregulation in human esophageal squamous carcinoma cells, but molecular studies on the precise signal pathways are still needed.

In order to identify kinase-specific expression patterns for tumor tissues, we analyzed 118 ESCC patients who received radical surgery. We utilized IHC methods to investigate the prognostic value of tumor-infiltrating IKBKE and to analyze the relationship between IKBKE expression and clinicopathological parameters in ESCC. It indicated the expression level of IKBKE in patients of the Discovery Group (all study subjects) (61.9% vs 38.1%). IKKε overexpression was positively correlated with poor prognosis, increased progression, and resistance to therapy. That was similar to our current observations. But our study firstly established that increased IKBKE expression in ESCC was significantly associated with advanced pTNM stages, lymph node metastasis, and a trend toward advanced pathological stages. Moreover, in Kaplan--Meier analysis, we presented that IKBKE expression had statistical relation with OS and DFS in 118 patients and increased IKKε expression was a poor prognosis with poor DFS and OS. It was independent of well-established clinical features, including lymphatic metastasis number (≥2), pTNM stages, and depth of invasion. Most importantly, we could indicate that IKBKE was overexpressed in ESCC tissue and it could be used as a predictive index for OS and PFS of ESCC patients. In the present study, we discovered the median DFS and OS were 18.3 and 25.4 months in the low IKBKE group, while 50.0 and 59.8 months in the high group (*p*\<0.001).

There were some shortcomings in our study. First, it was a retrospective cohort with a relatively small sample. Second, we could not confirm whether other cutoff values act as better predictors because we did not get esophageal specimens from healthy people. Third, we did not point out the causal relationship of IKBKE low expression and cancer development. In this study, we did not investigate the accurate mechanism underlying IKKε significant upregulation in human esophageal squamous carcinoma cells. Some of the future questions that should put a new premium on analyzing the role of IKBKE in tumor development are the following. Are there other substrates for these kinases that could explain their effect on cellular proliferation? The precise signal pathways are still needed.

Conclusion
==========

In this study, we revealed that IKKε protein expression was significantly upregulated in esophageal squamous carcinoma and positively correlated with clinical stage and tumor grade. This study identified IKBKE as a mediator of ESCC OS. It could be used to diagnose ESCC with high specificity and sensitivity. Meanwhile, it may therefore represent a new opportunity for drug development.
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![Inhibitor of NF-κB kinase epsilon (IKBKE, IKKε) was significantly upregulated in esophageal squamous cell carcinoma (ESCC). Immunohistochemistry assays of IKBKE expression in 118 ESCC patients. (**A**) Tumor tissues with low IKKε expression. (**B**) High IKBKE expression in ESCC tissues. The panels were observed at medium magnification (×200). Scale bars, 1:100 μm.](ott-11-1305Fig1){#f1-ott-11-1305}

![Inhibitor of NF-κB kinase epsilon (IKBKE) expression compared in tumor and adjacent nontumor tissues.](ott-11-1305Fig2){#f2-ott-11-1305}

![Kaplan--Meier analysis of inhibitor of NF-κB kinase epsilon (IKBKE) expression in 118 cases with esophageal squamous cell carcinoma. IKBKE expression was significantly associated with decreased disease-free survival (**A**) and overall survival (**B**).\
**Abbreviation:** Cum, cumulative.](ott-11-1305Fig3){#f3-ott-11-1305}

###### 

Clinical and histopathological characteristics of 118 esophageal squamous cell carcinoma patients

  Characteristic                                                Patients, n      Percentage
  ------------------------------------------------------------- ---------------- ------------
  Gender                                                                         
   Female                                                       23               19.5
   Male                                                         95               80.5
  Age (years)                                                                    
   Mean ± SD                                                    61.1±8.2         
   Median                                                       60.5             
  Tumor location                                                                 
   Cervical                                                     3                2.5
   Upper                                                        12               10.2
   Middle                                                       66               55.9
   Lower                                                        37               31.4
  Tumor length (cm)                                                              
   Mean ± SD                                                    3.84±1.59        
   Median (range)                                               3.5 (0.5--8.5)   
  T stage                                                                        
   T1                                                           17               14.4
   T2                                                           26               22.0
   T3                                                           67               56.8
   T4                                                           8                6.8
  Differentiation grade                                                          
   Well                                                         32               27.1
   Middle                                                       51               43.2
   Poor                                                         35               29.7
  Lymphatic metastasis                                                           
   Yes                                                          47               39.8
   No                                                           71               60.2
  Lymphatic metastasis number                                                    
   \<2                                                          21               17.8
   ≥2                                                           26               22.0
   Mean ± SD                                                    2.55±2.28        
   Median (range)                                               2 (1--10)        
  Tumor thrombus                                                                 
   Yes                                                          5                4.2
   No                                                           113              95.8
  TNM stage                                                                      
   I                                                            18               15.3
   II                                                           57               48.3
   III                                                          43               36.4
  IKBKE expression[a](#tfn1-ott-11-1305){ref-type="table-fn"}                    
   High                                                         73               61.9
   Low                                                          45               38.1

**Note:**

The proportion of IKBKE-expressing cells that exceeded 25% was grouped into high expression, and if not, then low expression.

**Abbreviations:** T, tumor; TNM, pathological tumor node metastasis; IKBKE, inhibitor of NF-κB kinase epsilon.

###### 

Correlation of IKBKE expression with clinicopathological parameters

  Characteristic          IKBKE low expression[a](#tfn4-ott-11-1305){ref-type="table-fn"}   IKBKE high expression[a](#tfn4-ott-11-1305){ref-type="table-fn"}   *p*-value
  ----------------------- ----------------------------------------------------------------- ------------------------------------------------------------------ -----------
  Gender                                                                                                                                                       0.122
   Male                   33                                                                62                                                                 
   Female                 12                                                                11                                                                 
  Age                                                                                                                                                          0.57
   \<60.5 years           21                                                                38                                                                 
   ≥60.5 years            24                                                                35                                                                 
  Tumor location                                                                                                                                               0.601
   Cervical/upper         7                                                                 8                                                                  
   Middle                 26                                                                40                                                                 
   Lower                  12                                                                25                                                                 
  Tumor length                                                                                                                                                 0.544
   \<3.84 cm              26                                                                38                                                                 
   ≥3.84 cm               19                                                                35                                                                 
  T stage                                                                                                                                                      0.071
   1 and 2                21                                                                22                                                                 
   3 and 4                24                                                                51                                                                 
  Differentiation grade                                                                                                                                        **0.045**
   Well                   16                                                                16                                                                 
   Middle                 13                                                                38                                                                 
   Poor                   16                                                                19                                                                 
  LN metastasis                                                                                                                                                0.129
   Negative               31                                                                40                                                                 
   Positive               14                                                                33                                                                 
  Positive LN                                                                                                                                                  0.313
   0                      31                                                                40                                                                 
   1                      8                                                                 13                                                                 
   2                      3                                                                 8                                                                  
   ≥3                     3                                                                 12                                                                 
  pTNM stage                                                                                                                                                   **0.023**
   I                      12                                                                6                                                                  
   II                     20                                                                37                                                                 
   III                    13                                                                30                                                                 
  Recurrence                                                                                                                                                   0.059
   No                     24                                                                26                                                                 
   Yes                    21                                                                47                                                                 
  Tumor thrombus                                                                                                                                               0.648
   No                     44                                                                69                                                                 
   Yes                    1                                                                 4                                                                  

**Notes:** Values in bold signify *p*\<0.05, considered significant.

The proportion of IKBKE-expressing cells that exceeded 25% was grouped into high expression, and if not, then low expression.

**Abbreviations:** IKBKE, inhibitor of NF-κB kinase epsilon; T, tumor; LN, lymph node; pTNM, pathological tumor node metastasis.

###### 

Univariate analysis of prognostic factors in ESCC with respect to DFS and OS

  Univariate analysis       Disease-free survival   Overall survival                          
  ------------------------- ----------------------- ------------------ ---------------------- -------------
  Gender                    1.270 (0.715--2.257)    0.415              1.311 (0.718--2.395)   0.378
  Age                       0.868 (0.539--1.399)    0.562              1.032 (0.616--1.727)   0.906
  Location                                                                                    
   Upper                    Ref                     0.148              Ref                    0.278
   Middle                   1.992 (0.963--4.118)    0.063              1.863 (0.845--4.107)   0.123
   Low                      1.128 (0.647--1.966)    0.671              1.136 (0.623--2.07)    0.678
  Length                    1.196 (0.743--1.928)    0.461              1.484 (0.886--2.486)   0.133
  Differentiation grade                                                                       
   High                     Ref                     0.396              Ref                    0.333
   Middle                   0.662 (0.341--1.284)    0.222              0.637 (0.328--1.236)   0.182
   Low                      0.974 (0.562--1.690)    0.926              0.971 (0.560--1.684)   0.916
  T stage (1, 2 vs 3, 4)    1.736 (1.034--2.914)    **0.037**          2.526 (1.380--4.622)   **0.003**
  Lymph nodes               2.438 (1.509--3.938)    \<**0.001**        2.861 (1.697--4.823)   \<**0.001**
  pTNM (I, II vs III, IV)   2.288 (1.416--3.697)    **0.001**          2.650 (1.576--4.456)   \<**0.001**
  IKBKE expression          1.804 (1.076--3.027)    **0.023**          2.118 (1.189--3.773)   **0.009**

**Note:** Values in bold signify *p*\<0.05, considered significant.

**Abbreviations:** CI, confidence interval; ESCC, esophageal squamous cell carcinoma; DFS, disease-free survival; HR, hazard ratio; OS, overall survival; Ref, reference; T, tumor; pTNM, pathological tumor node metastasis; IKBKE, inhibitor of NF-κB kinase epsilon.

###### 

Multivariate analysis of prognostic factors in ESCC with respect to DFS and OS

  Multivariate analysis   Disease-free survival   Overall survival                                      
  ----------------------- ----------------------- ------------------ ----------- ------- -------------- -----------
  Gender                                                                                                
   Male vs female         1.562                   0.827--2.953       0.17        1.701   0.874--3.311   0.118
  Age                                                                                                   
   \<61.1 vs ≥61.1        0.963                   0.559--1.660       0.893       1.366   0.765--2.438   0.292
  Tumor location                                                                                        
   Upper                  Ref                     Ref                0.243                              0.337
   Middle                 1.939                   0.891--4.216       0.095       1.909   0.808--4.511   0.141
   Lower                  1.358                   0.741--2.940       0.322       1.282   0.652--2.522   0.472
  T                                                                                                     
   1, 2 vs 3, 4           1.362                   0.753--2.462       0.307       2.05    0.998--4.215   0.051
  Differentiation grade                                                                                 
   Well                   Ref                     Ref                0.869                              0.573
   Middle                 0.943                   0.447--1.990       0.879       0.653   0.279--1.525   0.325
   Poor                   0.855                   0.470--1.554       0.607       0.777   0.415--1.454   0.43
  LN-M                                                                                                  
   Negative vs positive   1.533                   0.686--3.429       0.289       1.635   0.644--4.153   0.301
  pTNM                                                                                                  
   I, II vs III, IV       1.576                   0.686--3.622       0.283       1.467   0.551--3.905   0.443
  IKBKE                                                                                                 
   Low vs high            1.777                   1.034--3.054       **0.037**   2.078   1.138--3.796   **0.017**

**Note:** Values in bold signify *p*\<0.05, considered significant.

**Abbreviations:** CI, confidence interval; HR, hazard ratio; ESCC, esophageal squamous cell carcinoma; DFS, disease-free survival; OS, overall survival; Ref, reference; T, tumor; LN-M, lymph node metastasis; pTNM, pathological tumor node metastasis; IKBKE, inhibitor of NF-κB kinase epsilon.
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